Kyverna Therapeutics (KYTX) Accumulated Expenses (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Accumulated Expenses came in at $3.1 million in Q1 2026, up 1.14% YoY from $3.1 million in Q1 2025, and down 68.83% on a QoQ basis from $10.0 million in Q4 2025.
Kyverna Therapeutics (KYTX) Accumulated Expenses (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Accumulated Expenses rose 1.14% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 1.14% YoY) and the FY2025 annual result came in at $10.0 million, up 104.59% from the prior year.
- Accumulated Expenses fell to $3.1 million in Q1 2026, from $10.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $10.0 million in Q4 2025 to a low of $1.4 million in Q1 2024.
- A 4-year average of $4.4 million and a median of $3.8 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses surged 125.9% — and 2026, when it gained 1.14%.
- Tracing KYTX's Accumulated Expenses over 4 years: stood at $2.8 million in 2023, then jumped by 73.65% to $4.9 million in 2024, then soared by 104.59% to $10.0 million in 2025, then tumbled by 68.83% to $3.1 million in 2026.
- The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $10.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.48 Mn |
| Mar 31, 2026 | 3.11 Mn |
| Dec 31, 2025 | 9.99 Mn |
| Sep 30, 2025 | 6.96 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.44 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 2.81 Mn |